Tuberculosis: A relentless foe that has haunted humanity for millennia, continues to claim more lives annually than any other infectious disease. But what if we could understand its earliest moves, before symptoms even surface?
Scientists have engineered a groundbreaking 'lung-on-a-chip' model, a miniature replica of the human lung, to do just that. This innovative device is designed to breathe, and, remarkably, it's been infected with TB to study the disease's initial stages. The image showcases this lung-on-a-chip, with cell nuclei in blue, macrophages in magenta, endothelial cells in yellow, and tight junctions between epithelial and endothelial cells in white.
TB, despite medical advancements, remains a significant global health challenge. It's crucial to understand its mechanisms, particularly the often-mysterious delay before symptoms appear. This new model aims to demystify these early stages, potentially paving the way for more effective treatments. Moreover, it could reveal how genetic variations influence TB's impact, opening doors to personalized medicine.
Consider this: About a quarter of the world's population is carrying TB bacteria. While only a fraction will fall ill, that still translates to over 10 million new cases and over 1 million deaths each year worldwide.
TB's slow progression, with symptoms often taking months to manifest, makes studying its initial stages challenging. The researchers focused on the pulmonary alveoli, the tiny air sacs in the lungs where the immune cells and bacteria first clash. Max Gutierrez, from the Francis Crick Institute, explains that animal models have limitations due to differences in immune cell composition and disease progression, highlighting the need for alternative technologies.
This is where 'organ-on-a-chip' technology comes in. It allows scientists to simulate a full human organ within a microchip, offering an alternative to animal models. However, existing lung-on-a-chip systems have limitations, inspiring Gutierrez and his colleagues to explore a different approach.
Their innovation? A lung-on-a-chip built with genetically identical cells derived from a single human stem cell. This allows for a more accurate simulation of an individual's lung function and disease progression. First author Jakson Luk explains that they used human induced pluripotent stem cells to produce type I and II alveolar epithelial cells, grown on the top of a membrane, and vascular endothelial cells, grown on the bottom.
This offers a unique view into the 'black box' period of TB, the time between initial infection and symptom onset. When immune cells called macrophages were added to the chip before introducing TB, researchers observed macrophage clusters with necrotic cores – dead macrophages within a group of live ones.
But here's where it gets controversial... Five days post-infection, the endothelial and epithelial cell barriers collapsed, indicating a breakdown of air sac function.
And this is the part most people miss... The researchers also investigated how genetic differences affect TB responses. By removing the ATG14 gene, involved in degrading damaged cells, they found that macrophages lacking this gene were more susceptible to cell death and struggled to contain the TB bacteria.
More research is needed, but Luk and his colleagues see their chip as a crucial step toward personalized TB treatment and other infections. It could help understand how genetics influence treatment effectiveness. Gutierrez emphasizes the potential of this technology to advance personalized medicine.
What are your thoughts? Do you think this new technology will revolutionize TB treatment? Share your opinions in the comments below!
